About ActGen Pharma
ActGen Pharma is a company based in Mumbai (India) founded in 2008. It operates as a B2B. The company has 1 employees. ActGen Pharma operates in a competitive market with competitors including Laurus Labs, Symbiotec, Provepharm Life Solutions, Beijing Biostar Technologies and SeQuent, among others.
- Headquarter Mumbai, India
- Employees 1
- SectorsHealthcare
- Website actgen.in
- Legal Name Actgen Pharma Private Limited
- Date of Incorporation 08 Mar, 2008
- Jurisdiction Mumbai, Maharashtra, India
- Annual Revenue₹10.17 Cr
FY 2023 · +980% YoY
- Net Profit₹9.86 Cr
FY 2023 · 97% margin
- EBITDA₹9.86 Cr
FY 2023 · 97% margin
- Employee Count1
Associated legal entities of ActGen Pharma
ActGen Pharma operates through Actgen Pharma Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2023) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Actgen Pharma Private Limited CIN U24239MH2008PTC179859 | Active | 08 Mar 2008 | Mumbai, Maharashtra | ₹10.2 Cr | – | 2 | View details |
Board of directors of Actgen Pharma Private Limited (ActGen Pharma)
Actgen Pharma Private Limited is the primary company behind ActGen Pharma. The board of Actgen Pharma Private Limited currently have 2 directors; the longest-serving is Kantilal Mangalchand Hiran, appointed in 2023. 8 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Kantilal Mangalchand Hiran DIN 00186885 | Director | 05 Sep 2023 | 3 yrs 1 mo | Actgen Pharma Private Limited |
| Dariyadevi Kantilal Hiran DIN 00187107 | Director | 06 Nov 2023 | 2 yrs 11 mo | Actgen Pharma Private Limited |
Financials of ActGen Pharma
Figures of Actgen Pharma Private Limited, the primary company behind ActGen Pharma, for FY 2023. Revenue was ₹10.17 Cr (+980% year on year). Net profit was ₹9.86 Cr (97% margin). EBITDA was ₹9.86 Cr (97% margin). Revenue has grown at a compounded annual rate of +70% over three years.
- ₹10.17 CrRevenue · FY 2023 · +980% YoY
- ₹9.86 CrNet profit · 97% margin
- ₹9.86 CrEBITDA · 97% margin
- ₹9.00 CrPaid-up capital
- +70%Revenue CAGR, 3 years
Balance sheet, profit and loss, cash flow and ratios of Actgen Pharma Private Limited are on its company page.
Detailed financial statements for ActGen Pharma
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Competitors of ActGen Pharma
ActGen Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Laurus Labs, Symbiotec, Provepharm Life Solutions, Beijing Biostar Technologies and SeQuent, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| lauruslabs.com | 2005 | Hyderabad, India | $229.73M | 6,035 | Pharmaceutical and biotechnology company | |
| symbiotec.in | 2002 | Indore, India | $61.01M | 1,822 | Non-sterile steroid hormone-based APIs and intermediates are manufactured. | |
| provepharm.com | 1998 | Marseille, France | $145.93M | – | APIs and drug products are developed and valorized in pharmaceuticals. | |
| biostar-pharm.com | 2002 | Beijing, China | $135.23M | – | APIs, intermediates, and biochemical reagents are developed and manufactured. | |
| sequent.in | 2002 | Bengaluru, India | – | – | APIs are developed and manufactured for therapeutic areas. | |
| sterlingpharmasolutions.com | 2016 | Dudley, United Kingdom | – | 560 | Contract development, manufacturing, and analytical services for APIs are offered. | |
| snapdragonchemistry.com | 2014 | Cambridge, United States | – | 43 | Drug discovery and development service provider | |
| jubilantpharma.com | 1978 | Noida, India | – | – | Pharmaceuticals, APIs, and radiopharmaceuticals are manufactured by the company. | |
| hikal.com | 1988 | Mumbai, India | – | 355 | APIs and intermediates are produced via custom synthesis and research. |
Detailed competitors of ActGen Pharma
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Similar companies to ActGen Pharma
10 companies that operate in the same segment as ActGen Pharma (Pharmaceuticals & Distribution), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Pharmaceutical products are manufactured and marketed worldwide. | 1891 | Kenilworth, Warwickshire, United Kingdom | – | USD 64.93 B | 781 | |
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | 2014 | New York, New York, United States | USD 1.3 B | USD 8.26 M | 750 | |
Developer of pharmaceutical products for treating multiple diseases | 1980 | Thousand Oaks, California, United States | – | USD 33.23 B | 28,000 | |
Biopharmaceutical research and drug development are conducted globally by AbbVie. | 2012 | Chicago, Illinois, United States | – | USD 61.16 B | 55,000 | |
Traditional pharmaceutical medicines are developed for multiple health fields. | 1876 | United States | – | USD 65.18 B | 47,000 | |
Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others | 1987 | Foster City, California, United States | – | USD 29.45 B | 17,600 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 215.5 M | USD 29.62 M | 225 | |
Developer of medical devices, generic pharmaceuticals, and nutrition products | 1888 | Libertyville, Illinois, United States | – | USD 44.33 B | 3,710 | |
Medicines and health products are retailed through pharmacy outlets. | 2006 | Hyderabad, Telangana, India | USD 268.78 M | USD 734.57 M | 25,010 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about ActGen Pharma
ActGen Pharma was founded in 2008.
ActGen Pharma is headquartered in Mumbai, India. It is registered at Mumbai, Maharashtra, India.
ActGen Pharma has 1 employees.
The primary company behind ActGen Pharma, Actgen Pharma Private Limited, reported revenue of ₹10.17 Cr for FY 2023, up 980% year on year.
ActGen Pharma manufactures active pharmaceutical ingredients (apis), focusing on providing healthcare solutions, producing pharmaceutical products, producing manufactured goods, and active pharmaceutical ingredients. It serves clients with dedicated solutions, emphasizing quality, innovation, and sustainable growth in its core markets. It continues to evolve, meeting industry challenges with strategic approaches.
ActGen Pharma's top competitors include Laurus Labs, Symbiotec and Beijing Biostar Technologies.
ActGen Pharma operates through Actgen Pharma Private Limited.
The legal entities of ActGen Pharma currently have 2 directors, including Kantilal Mangalchand Hiran, Dariyadevi Kantilal Hiran.